🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Lake Street sees buying opportunity in Personalis, sets price target

EditorAhmed Abdulazez Abdulkadir
Published 30/04/2024, 15:26
PSNL
-

On Tuesday, Lake Street Capital Markets began coverage on biotechnology company Personalis, Inc. (NASDAQ:PSNL), assigning a Buy rating to the stock with a price target of $4.00. The firm identified the recent introduction of NeXT Personal Dx into the minimal residual disease (MRD) market as a pivotal moment for the company, anticipating it will lead to significant developments in data generation, scientific publications, and eventual adoption within the oncology sector.

Lake Street's analysis suggests that the considerable changes made by Personalis since Chris Hall took over as CEO have not been adequately factored into the company's stock price. The shares have seen a significant decline, dropping by 48% since Hall's appointment to the leadership role. This downturn in the stock's performance is viewed by Lake Street as an opportunity for investors to purchase shares at a value.

The analyst's commentary highlighted the potential of NeXT Personal Dx to impact the MRD market. The expectation is that the product's launch will pave the way for further research and validation, which in turn could lead to broader acceptance and use by cancer specialists.

The investment firm's initiation of coverage comes at a time when Personalis is navigating a challenging market environment. The company's strategic shift and the recent product launch are seen as key drivers that could alter the company's trajectory and enhance its market position.

InvestingPro Insights

In light of Lake Street Capital Markets' optimistic outlook on Personalis, Inc. (NASDAQ:PSNL), real-time data and insights from InvestingPro provide a more nuanced picture of the company's financial health and market performance. With a market capitalization of $69.65 million, Personalis is a small-cap biotech firm that has shown a revenue growth of 12.97% over the last twelve months as of Q4 2023, suggesting a growing interest in its offerings. Despite this growth, the company's stock price has been volatile, with a significant price uptick of 41.34% over the last six months, yet a year-to-date price total return of -35.24%.

InvestingPro Tips highlight two key factors for investors to consider: Personalis holds more cash than debt on its balance sheet, which may provide some financial stability, and analysts have revised their earnings upwards for the upcoming period, signaling potential optimism in the company's financial future. On the other hand, Personalis has been quickly burning through cash and is not expected to be profitable this year, which may raise concerns about its long-term sustainability.

For investors intrigued by Lake Street's analysis, these additional metrics and tips from InvestingPro could be valuable in making a more informed decision. There are 11 more InvestingPro Tips available for Personalis, which can be accessed with a subscription. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing a comprehensive set of tools and insights to navigate the complexities of investing in the biotech sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.